Danimer Scientific (DNMR) 10-Q 16 Aug 21 2021 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 12, 2021
Document Information [Line Items]
Entity Registrant Name	DANIMER SCIENTIFIC, INC.
Entity Central Index Key	0001779020
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-39280
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	84-1924518
Entity Address, Address Line One	140 Industrial Boulevard
Entity Address, City or Town	Bainbridge
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	39817
City Area Code	229
Local Phone Number	243-7075
Title of 12(b) Security	Class A Common stock, $0.0001 par value per share
Trading Symbol	DNMR
Security Exchange Name	NYSE
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		97,732,079

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 416,355	$ 377,581
Accounts receivable, net	10,069	6,605
Inventories	17,653	13,642
Prepaid expenses and other current assets	4,611	3,089
Contract assets	3,018	1,466
Total current assets	451,706	402,383
Property, plant and equipment, net	159,983	106,795
Patents, net	1,819	1,801
Right-of-use assets	16,546	19,387
Leverage loans receivable	13,408	13,408
Restricted cash	524	2,316
Loan fees	1,548	0
Other assets	71	111
Total assets	645,605	546,201
Current liabilities
Accounts payable	18,970	10,610
Accrued liabilities	5,901	9,220
Unearned revenue and contract liabilities	822	2,455
Current portion of lease liability	2,947	3,000
Current portion of long-term debt, net	333	25,201
Total current liabilities	28,973	50,486
Private warrants liability	59,302	82,860
Long-term lease liability, net	20,581	24,175
Long-term debt, net	29,576	31,386
Other long-term liabilities	625	1,250
Total liabilities	139,057	190,157
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized: 97,732,079 and 84,535,640 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	9	8
Additional paid-in capital	620,808	414,819
Accumulated deficit	(114,269)	(58,783)
Total stockholders’ equity	506,548	356,044
Total liabilities and stockholders’ equity	$ 645,605	$ 546,201

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	97,732,079	84,535,640
Common Stock, Shares, Outstanding	97,732,079	84,535,640

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue:
Total revenue	$ 14,471	$ 11,873	$ 27,652	$ 22,471
Costs and expenses:
Cost of revenue	12,460	8,441	24,185	15,870
Selling, general and administrative	19,079	2,828	29,199	5,808
Research and development	3,975	2,128	6,594	3,375
Gain (loss) on sale of assets	33	(9)	33	(9)
Total costs and expenses	35,547	13,388	60,011	25,044
Loss from operations	(21,076)	(1,515)	(32,359)	(2,573)
Nonoperating income (expense):
Gain (loss) on remeasurement of private warrants	58,740	0	(21,957)	0
Interest expense, net	(222)	(384)	(422)	(1,097)
Gain on forgiveness of debt	1,776	0	1,776	0
Loss on debt extinguishment	0	0	(2,604)	0
Other income (expense), net	30	99	80	189
Total nonoperating income (expenses)	60,324	(285)	(23,127)	(908)
Income (loss) before income taxes	39,248	(1,800)	(55,486)	(3,481)
Income tax expense	0	0	0	0
Net income (loss)	$ 39,248	$ (1,800)	$ (55,486)	$ (3,481)
Net loss per share:
Basic net income (loss) per share	$ 0.44	$ (0.06)	$ (0.64)	$ (0.12)
Diluted net income (loss) per share	$ 0.39	$ (0.06)	$ (0.64)	$ (0.12)
Weighted average number of shares used to compute basic net income (loss) per share	88,806,086	29,005,309	86,760,615	28,386,948
Dilutive effect of warrants and stock options	12,718,858	0	0	0
Weighted average number of shares used to compute diluted net income (loss) per share	101,524,944	29,005,309	86,760,615	28,386,948
Products
Revenue:
Total revenue	$ 11,294	$ 10,576	$ 22,318	$ 19,755
Services
Revenue:
Total revenue	$ 3,177	$ 1,297	$ 5,334	$ 2,716

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Balance, beginning of period at Dec. 31, 2019		$ 3	$ 66,503	$ (49,930)
Fair value of private warrants converted to public warrants			0
Exercise of warrants, net of issuance costs			0
Stock-based compensation			302
Stock issued under stock compensation plan			0
Beneficial conversion feature on convertible notes			93
Issuance of common stock, net of issuance costs		0	25,007
Net income (loss)	$ (3,481)			(3,481)
Balance, end of period at Jun. 30, 2020	38,497	3	91,905	(53,411)
Balance, beginning of period at Mar. 31, 2020		3	91,750	(51,611)
Fair value of private warrants converted to public warrants			0
Exercise of warrants, net of issuance costs			0
Stock-based compensation			155
Stock issued under stock compensation plan			0
Beneficial conversion feature on convertible notes			0
Issuance of common stock, net of issuance costs		0	0
Net income (loss)	(1,800)			(1,800)
Balance, end of period at Jun. 30, 2020	38,497	3	91,905	(53,411)
Balance, beginning of period at Dec. 31, 2020	356,044	8	414,819	(58,783)
Fair value of private warrants converted to public warrants			45,515
Exercise of warrants, net of issuance costs			138,202
Stock-based compensation			20,696
Stock issued under stock compensation plan			2,466
Beneficial conversion feature on convertible notes			0
Issuance of common stock, net of issuance costs		1	(890)
Net income (loss)	(55,486)			(55,486)
Balance, end of period at Jun. 30, 2021	506,548	9	620,808	(114,269)
Balance, beginning of period at Mar. 31, 2021		8	435,782	(153,517)
Fair value of private warrants converted to public warrants			31,593
Exercise of warrants, net of issuance costs			138,202
Stock-based compensation			14,031
Stock issued under stock compensation plan			1,275
Beneficial conversion feature on convertible notes			0
Issuance of common stock, net of issuance costs		1	(75)
Net income (loss)	39,248			39,248
Balance, end of period at Jun. 30, 2021	$ 506,548	$ 9	$ 620,808	$ (114,269)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Net loss	$ (55,486,000)	$ (3,481,000)
Adjustments to reconcile net loss to net cash used in operating activities
Loss on remeasurement of private warrants	(21,957,000)	0
Share-based compensation	20,696,000	302,000
Depreciation and amortization	4,311,000	1,809,000
Loss on write-off of deferred loan costs	1,900,000	0
Amortization of debt issuance costs and debt discounts	207,000	852,000
Single lease cost (benefit)	(806,000)	194,000
Gain on forgiveness of debt	1,776,000	0
Other	66,000	381,000
Changes in operating assets and liabilities - net of acquisitions:
Accounts payable	1,967,000	(592,000)
Contract assets	(1,552,000)	0
Unearned revenue and contract liabilities	(1,633,000)	(907,000)
Prepaid expenses and other current assets	(1,520,000)	(1,879,000)
Accounts receivable, net	(3,464,000)	(1,152,000)
Accrued and other long-term liabilities	(3,537,000)	346,000
Inventories	(4,011,000)	(5,780,000)
Other assets	40,000	(482,000)
Net cash used in operating activities	(22,641,000)	(10,389,000)
Cash flows from investing activities
Purchases of property, plant and equipment	(51,906,000)	(19,079,000)
Proceeds from Sale of Property, Plant, and Equipment	340,000	9,000
Net cash used in investing activities	(51,566,000)	(19,070,000)
Cash flows from financing activities
Proceeds from exercise of warrants, net of issuance costs	138,202,000	0
Proceeds from exercise of stock options	2,375,000	0
Proceeds from long-term debt	169,000	4,015,000
Proceeds from employee stock purchase plan	92,000	0
Proceeds from issuance of common stock, net of issuance costs	(890,000)	25,007,000
Cash paid for debt issuance costs	(1,684,000)	(18,000)
Principal payments on long-term debt	(27,075,000)	(811,000)
Net cash (used in) provided by financing activities	111,189,000	28,193,000
Net (decrease) increase in cash and cash equivalents and restricted cash	36,982,000	(1,266,000)
Cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash-beginning of period	379,897,000	9,278,000
Cash and cash equivalents and restricted cash-end of period	416,879,000	8,012,000
Supplemental Cash Flow Information [Abstract]
Cash paid for interest, net of interest capitalized	242,000	0
Cash paid for operating leases	1,589,000	1,270,000
Noncash Investing and Financing Items [Abstract]
Changes in accounts payable and accrued liabilities related to purchase of property, plant and equipment	$ 5,983,000	$ (5,831,000)

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Note 1. Basis of Presentation Description of Business Danimer Scientific, Inc. (“Danimer”) together with its subsidiaries (collectively referred to as the “Company”) is a performance polymer company specializing in bioplastic replacements for traditional petroleum-based plastics. Our common stock is listed on the New York Stock Exchange under the symbol “DNMR”. Financial Statements We have prepared these condensed consolidated financial statements (“Financial Statements”) in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the rules and regulations of the SEC. In the opinion of management, our Financial Statements reflect all adjustments, which are of a normal recurring nature, necessary to present fairly our financial position, results of operations, stockholders’ equity, and cash flows at the dates and for the periods presented. Our Financial Statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our Amended Annual Report on Form 10-K/A for the year ended December 31, 2020. Results for interim periods are not necessarily indicative of the results for the year. We have made certain reclassifications to the prior period presentation in order to conform to the current presentation. We cannot predict the ongoing impact of the COVID-19 pandemic on the increased volatility in global economic and political environments, market demand for our products, supply chain disruptions, possible workforce availability, exchange rate and commodity price volatility and availability of financing, and their impact to our total revenue, production volumes, costs and overall financial condition and available funding. In preparing our Financial Statements in conformity with U.S. GAAP, we have considered and, where appropriate, reflected the effects of the COVID-19 pandemic on our operations. The pandemic continues to provide significant challenges to the U.S. and global economies. Recently Issued or Adopted Accounting Pronouncements There have been no new accounting pronouncements not yet effective or adopted in the current period that we believe have a significant effect, or potential significant effect, on our Financial Statements.

Business Combination

Business Combination	6 Months Ended
	Jun. 30, 2021
Business Combinations [Abstract]
Business Combination	Note 2. Business Combination Live Oak Acquisition Corp. (“Live Oak”) was incorporated in the State of Delaware on May 24, 2019 as a special purpose acquisition company formed for the purpose of effecting a business combination with one or more businesses. Live Oak completed its initial public offering in May 2020. On December 29, 2020, Live Oak consummated a business combination (“Business Combination”) with Meredian Holdings Group, Inc. (“Legacy Danimer”) with Legacy Danimer surviving the merger as a wholly owned subsidiary of Live Oak. In connection with the Business Combination, Live Oak changed its name to Danimer Scientific, Inc. For financial accounting and reporting purposes, Legacy Danimer was deemed the accounting acquirer, Live Oak was treated as the accounting acquiree, and the Business Combination was accounted for as a reverse recapitalization. Effectively, the Business Combination was treated as the equivalent of Legacy Danimer issuing stock for the net assets of Live Oak, accompanied by a recapitalization. Under this method of accounting, the historical financial statements of Legacy Danimer are our historical financial statements. The net assets of Live Oak are stated at historical costs, with no goodwill or other intangible assets recorded, and were consolidated with Legacy Danimer’s financial statements on December 29, 2020.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Inventories	Note 3. Inventories Inventories consisted of the following: June 30, December 31, (in thousands) 2021 2020 Raw materials $ 7,650 $ 6,825 Work in progress - 133 Finished goods and related items 10,003 6,684 Total inventories $ 17,653 $ 13,642

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, net	Note 4. Property, Plant and Equipment Property, plant and equipment, net, consisted of the following: Estimated Useful Life June 30, December 31, (in thousands) (Years) 2021 2020 Land and improvements 20 $ 92 $ 92 Leasehold improvements Shorter of useful 21,021 20,932 Buildings 15 - 40 2,089 2,089 Machinery and equipment 5 - 20 82,489 64,164 Motor vehicles 7 - 10 874 693 Furniture and fixtures 7 - 10 229 221 Office equipment 3 - 10 2,110 2,089 Construction in progress N/A 74,771 36,146 183,675 126,426 Accumulated depreciation and amortization ( 23,692 ) ( 19,631 ) Property, plant and equipment, net $ 159,983 $ 106,795 We reported depreciation and amortization expense (which included amortization of patents) as follows: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2021 2020 2021 2020 Cost of revenue $ 1,951 $ 753 $ 3,790 $ 1,436 Selling, general and administrative 177 31 273 60 Research and development 83 155 248 313 Total depreciation and amortization expense $ 2,211 $ 939 $ 4,311 $ 1,809 Construction in progress consists primarily of the conversion and build-out of our new facility in Winchester, Kentucky. Property, plant and equipment includes capitalized interest of $ 5.3 million and $ 5.1 million as of June 30, 2021 and December 31, 2020, respectively. For the three and six months ended June 30, 2021 and 2020, interest costs of $ 0.1 million and $ 0.3 million and $ 1.1 million and $ 1.8 million, respectively, were capitalized to property, plant and equipment. At December 31, 2020 , prepaid expenses and other current assets included $ 0.8 million of equipment classified as held for sale. We sold this equipment in April 2021 at a loss of approximately $ 33 thousand.

Patents

Patents	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Note 5. Patents The majority of our patents were purchased from another commercial corporation, but we have also developed our own patents. We capitalize patent defense and application costs. Patent costs are amortized on a straight-line basis over their estimated useful lives, which range from 13 to 16 years . At June 30, 2021 and December 31, 2020, the gross carrying value of patents subject to amortization was approximately $ 7.8 million. Accumulated amortization was approximately $ 6.7 million and $ 6.5 million at June 30, 2021 and December 31, 2020, respectively. Amortization expense was $ 0.1 million and $ 0.2 million for the three and six months ended June 30, 2021 and 2020 and is included in research and development costs. At June 30, 2021 and December 31, 2020, capitalized patent acquisition and defense costs not yet subject to amortization were $ 0.7 million and $ 0.5 million, respectively.

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2021
Accrued Liabilities [Abstract]
Accrued Liabilities	Note 6. Accrued Liabilities The components of accrued liabilities were as follows: June 30, December 31, (in thousands) 2021 2020 Compensation and related expenses $ 1,407 $ 5,395 Legal settlement 1,250 1,250 Transaction costs and other legal fees 1,563 1,293 Construction in progress expenditures - 531 Other 1,681 751 Total accrued liabilities $ 5,901 $ 9,220

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 7. Income Taxes Our effective income tax rate was zero for the three and six months ended June 30, 2021 and 2020 because we reported taxable losses in each period and continued to provide a full valuation allowance against our net deferred tax assets. In assessing the realizability of deferred income tax assets, we consider whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods at which time those temporary differences become deductible. In making valuation allowance determinations, we consider all available evidence, positive and negative, affecting specific deferred tax assets, including the scheduled reversal of deferred income tax liabilities, projected future taxable income, the length of carry-back and carry-forward periods, and tax planning strategies in making this assessment.

Operating Leases

Operating Leases	6 Months Ended
	Jun. 30, 2021
Disclosure Text Block [Abstract]
Operating Leases	Note 8. Operating Leases We reported operating lease costs as follows: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2021 2020 2021 2020 Cost of revenue $ 83 $ 244 $ 613 $ 460 Selling, general and administrative ( 91 ) 496 ( 40 ) 951 Research and development 144 129 288 245 Total operating lease cost $ 136 $ 869 $ 861 $ 1,656

Private Warrants

Private Warrants	6 Months Ended
	Jun. 30, 2021
Text Block [Abstract]
Private Warrants	Note 9. Private Warrants At June 30, 2021 and December 31, 2020, there were 3,915,893 and 6,000,000 outstanding warrants, respectively, to purchase shares of our common stock at an exercise price of $ 11.50 per share, subject to adjustments, that had been privately placed prior to the Business Combination ( “Private Warrants” ). The warrants are exercisable at any time after May 7, 2021 , and we do not have any right to compel the exercise or redemption of the Private Warrants. All Private Warrants transferred, assigned, or sold to anyone other than certain affiliates of Live Oak prior to June 16, 2021 became Public Warrants (as defined in Note 11). On December 28, 2025 , any remaining outstanding Private Warrants will expire. During the quarters ended June 30, 2021 and March 31, 2021, respectively, holders of 1,565,260 and 518,847 Private Warrants sold them and the Private Warrants became Public Warrants. We valued these Private Warrants on each sale date using the Black Scholes model and reclassified the fair value of each Private Warrant to additional paid-in capital. The Private Warrants meet the definition of a derivative instrument and are reported as liabilities at June 30, 2021 and December 31, 2020 , with changes in the fair value of the private warrants recorded in earnings. The Private Warrants are Level 3 financial instruments. A rollforward of the Private Warrants liability is below. (in thousands) Balance at December 31, 2020 $ ( 82,860 ) Loss on remeasurement of Private Warrants ( 80,697 ) Fair value of Private Warrants sold 13,922 Balance at March 31, 2021 ( 149,635 ) Gain on remeasurement of Private Warrants 58,740 Fair value of Private Warrants sold 31,593 Balance at June 30, 2021 $ ( 59,302 ) The table below sets forth the inputs we used in our Black-Scholes models for Private Warrant valuations and the fair values determined. As Of Three Months Ended Six Months Ended As Of June 30, 2021 June 30, 2021 June 30, 2021 December 31, 2020 Share price of our common stock $ 25.05 $ 17.45 - $ 38.33 $ 17.45 - $ 44.26 $ 23.51 Expected annual dividend yield (1) 0 % 0 % 0 % 0 % Expected volatility (2) 40 % 40 % 40 % 40.0 % Risk-free rate of return (3) 0.76 % 0.76 % 0.76 % - 0.85 % 0.36 % Expected warrant term (years) (4) 4.50 4.50 - 4.73 4.50 - 4.99 4.99 Fair value determined per warrant $ 15.14 $ 8.53 - $ 27.82 $ 8.53 - $ 33.65 $ 13.81 (1) We have not paid and do not currently anticipate paying a cash dividend on our common stock. (2) We estimated expected volatilities using stock data for select peer public companies over a timeframe similar to the expected term. We selected peer companies using our judgment and as such, expected volatility is a Level 3 input. (3) We estimated risk-free rates based on the expected terms using the U.S. Treasury yield curve in effect as of the valuation dates. (4) The expected warrant terms are equal to the remaining contractual life of the Private Warrants at each measurement date.

Debt

Debt	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Long-Term Debt	Note 10. Debt The components of long-term debt were as follows: June 30, December 31, (in thousands) 2021 2020 2019 Term Loan $ - $ 27,000 Subordinated Term Loan 10,205 10,171 NMTC notes 21,000 21,000 Paycheck Protection Program loan - 1,776 Asset Based Lending Agreement - - Vehicle and equipment notes 434 329 Mortgage notes 254 266 Total $ 31,893 $ 60,542 Less: Total unamortized debt issuance costs ( 1,984 ) ( 3,955 ) Less: Current cash maturities net of current portion of debt issuance costs ( 333 ) ( 25,201 ) Total long-term debt $ 29,576 $ 31,386 2019 Term Loan In March 2019, we entered into a credit agreement (“2019 Term Loan”) for a $ 30 million term loan maturing on October 13, 2023 . Principal payments were due in quarterly payments of $ 375,000 beginning April 1, 2019 with the outstanding principal balance due at maturity. The 2019 Term Loan was secured by all real and personal property of Danimer Scientific Holdings, LLC (“DSH”) and its subsidiaries. The 2019 Term Loan provided for financial covenants including a maximum capital expenditures limit, leverage ratio and fixed charge coverage ratio, each of which became more restrictive over time. In July 2020, we modified the 2019 Term Loan such that the applicable margin in the interest rate formula (formerly calculated as the greater of (a) 2.25 % or (b) three month LIBOR, plus 4.5 %) changed from 4.5% to a five-level tiered amount ranging from 4.5% if the consolidated senior leverage ratio, as defined in the 2019 Term Loan, was less than 1.5, to as high as 6.35 % if the consolidated senior leverage ratio was greater than 2.25. When the amendment was executed, the applicable margin was 6.35%. On January 29, 2021, we voluntarily paid off and terminated our 2019 Term Loan. All related liens and security interests in our assets and guarantees were terminated and released. We settled the 2019 Term Loan for $ 27.7 million including the outstanding principal amount of $ 27.0 million, a prepayment fee of $ 0.5 million and $ 0.2 million in accrued unpaid interest. We recognized a loss of $ 2.6 million upon extinguishment due to the prepayment and related fees and the write-off of unamortized debt issuance costs. Subordinated Term Loan In March 2019, we, through a subsidiary, entered into a subordinated second credit agreement (“Subordinated Term Loan”) for $ 10 million in term loans consisting of two loans in the amounts of $ 5.5 million and $ 4.5 million with essentially the same terms. The term loans mature on February 13, 2024 and require monthly interest only payments, with the outstanding principal balance due at maturity. The base interest rate is the “Prime Rate” as quoted by the Wall Street Journal (adjusted each calendar quarter; 3.25 % and 3.25 % at June 30, 2021 and December 31, 2020, respectively) plus 2.75 %. We have the option to pay up to two percent ( 2 %) in any interest payable in any fiscal quarter by adding such interest payment to the principal balance of the related note (“PIK Interest”). During the year ended December 31, 2020, we used the PIK Interest option and an additional $ 0.2 million was included in the principal balance at December 31, 2020. The Subordinated Term Loan provided for financial covenants including a maximum capital expenditures limit, leverage ratio, fixed charge coverage ratio and adjusted EBITDA covenants, certain of which became more restrictive over time. On March 18, 2021, we amended the Subordinated Term Loan to, among other things, change the base rate from the prime rate to LIBOR, lower the applicable margin to 2 % from 2.75%, remove certain prepayment requirements, convert the financial covenants to “springing” financial covenants that do not apply as long as the subsidiary has at least $ 10 million of unrestricted cash on deposit, increase the capital expenditure covenant, and restrict our ability to prepay the loan until after July 1, 2022. The Subordinated Term Loan remains secured by all real and personal property of DSH and its subsidiaries but is subordinated to all other existing lenders. At June 30, 2021, we were in compliance with all financial covenants. New Markets Tax Credit Transactions We have entered into financing arrangements under the New Markets Tax Credit (“NMTC”) program with various unrelated third-party financial institutions (individually and collectively referred to as “Investors”) during 2012, 2013 and 2019. The NMTC program was provided for in the Community Renewal Tax Relief Act of 2000 (the “Act”) to induce capital investment in qualified lower income communities. The Act permits taxpayers to claim credits against their federal income taxes for up to 39 % of qualified investment in the equity of the community development entities (“CDEs”). CDEs are privately managed investment institutions that are certified to make qualified low-income community investments. These financing arrangements were structured with the Investors, their wholly owned investment funds (“Investment Funds”) and their wholly owned CDEs in connection with our participation in qualified transactions under the NMTC program. In each of the financing arrangements, we loaned money (in the form of leverage loans) to the Investment Funds and the Investors invested in the Investment Funds. Each Investment Fund then contributed the funds from our loan and the Investor’s investment to a CDE. Each CDE then loaned the contributed funds to a wholly owned subsidiary of the Company. The Investors are entitled to substantially all of the benefits derived from the tax credits. The NMTC tax credits are subject to recapture for a compliance period of seven years. During the compliance period, we are required to comply with various regulations and contractual provisions that apply to the NMTC arrangements. We do not expect the maximum potential amount of future payments under this indemnification to exceed the face amount of the related debt, net of leverage loans receivable. We believe that the likelihood of a required payment under this indemnification is remote. Paycheck Protection Program Loan In April 2020, we received $ 1.8 million under the Paycheck Protection Program (“PPP Loan”). The PPP Loan had a two-year term and bore interest at a rate of 1.0 % per annum. Monthly principal and interest payments were deferred for six months after the date of disbursement. The promissory note issued in connection with the PPP Loan contained events of default and other provisions customary for a loan of this type. On December 11, 2020, we submitted an application for forgiveness of the PPP Loan. In connection with the Business Combination, we entered into an escrow agreement with the PPP lender and on December 29, 2020 we deposited in escrow $ 1.8 million, which represented the principal, accrued interest, and escrow fee to pay the loan in full. We classified the amounts in escrow as restricted cash at December 31, 2020. During the quarter ended June 30, 2021, our PPP Loan was forgiven and we received the escrow balance, net of associated fees, of $ 1.8 million and as a result recognized a gain of $ 1.8 million. Asset-based Lending Arrangement On April 29, 2021, we entered into a credit facility (“Credit Agreement”) with Truist Bank that includes a $ 20.0 million variable interest rate asset-based lending arrangement and a $ 1.0 million capital expenditure line of credit with customary terms and conditions. The amount of the revolving commitment available for borrowing at any given time is subject to a borrowing base formula that is based upon our qualifying accounts receivable and inventory. These arrangements mature on April 29, 2026 . Interest on any borrowings is payable monthly and is calculated, at our election, using either a base rate (as defined in the Credit Agreement) plus an applicable margin of 1.50 % for revolving loans and 1.75 % for equipment loans, or a LIBOR market index rate (“LMIR”) (as defined) plus an applicable margin of 2.50 % for revolving loans and 2.75 % for equipment loans. If we maintain a trailing twelve month consolidated fixed charge coverage ratio (as defined) of 1.1:1.0 or better and no event of default exists, then the applicable margins for base rate revolving loans and LMIR rate loans are 1.00 % and 2.00 %, respectively. The Credit Agreement contains customary affirmative and negative covenants, with certain permitted exceptions, which, among other things:  require us to deliver financial statements and other information and to provide notice of certain material events,  contain certain restrictions on the conduct of our business, the management of cash, and the administration of accounts, inventory and equipment,  restrict our ability to own, hold and acquire assets; incur debt and liens; to make investments and payments; to effect fundamental corporate changes, to sell assets, and to enter into certain other types of transactions or agreements. After October 29, 2023, or sooner at our election in order to increase availability under the borrowing base formula, we are required to maintain a trailing twelve month consolidated fixed charge coverage ratio of at least 1.1:1.0. Also on April 29, 2021, we entered into a guaranty and security agreement with Truist Bank. Pursuant to this security agreement, we granted a security interest in substantially all of the personal property to secure the obligations under the Credit Agreement and we guaranteed, on an unsecured basis, all of the obligations under the Credit Agreement.

Equity

Equity	6 Months Ended
	Jun. 30, 2021
Stockholders' Equity Note [Abstract]
Equity	Note 11. Equity Outstanding Shares The following table summarizes the common stock activity for the three and six months ended June 30, 2021 and 2020: Three Months Ended Six Months Ended June 30, June 30, 2021 2020 (1) 2021 2020 (1) Common stock: Balance, beginning of period 85,339,145 29,005,309 84,535,640 25,371,186 Issuance of common stock 12,392,934 - 13,196,439 3,634,123 Balance, end of period 97,732,079 29,005,309 97,732,079 29,005,309 (1) Retroactively restated for Business Combination Public Warrants At December 31, 2020, there were 10,000,000 outstanding publicly traded warrants to purchase shares of our common stock with an exercise price of $ 11.50 per share, subject to adjustments (“Public Warrants”). The Public Warrants were exercisable and potentially redeemable after May 7, 2021. We could redeem the Public Warrants at a price of $ 0.01 per warrant upon a minimum of 30 days’ prior written notice of redemption, if and only if the last sale price of our common stock equaled or exceeded $ 18.00 per share for any 20-trading days within a 30-trading day period ended three business days before we sent the notice of redemption to the warrant holders. This requirement was met and on May 14, 2021, we notified holders of the Public Warrants of our intent to redeem them on June 16, 2021. As a result, 12,033,169 Public Warrants, including some Public Warrants that had initially been Private Warrants, were exercised and 50,965 Public Warrants were redeemed. Net of fees, we collected $ 138.2 million in connection with the exercises and redemptions. The Public Warrants qualified as equity instruments and we included them in additional paid-in capital at December 31, 2020. Non-Plan Legacy Danimer Options and Warrants Prior to 2017, Legacy Danimer had issued 208,183 stock options that were not a part of either the 2016 Executive Plan or the 2016 Omnibus Plan. These options had a weighted average exercise price of $ 30 per share. On December 29, 2020, the then-remaining 30,493 of these options were converted to options to purchase 279,253 shares of our common stock with a weighted average exercise price of $ 3.28 per share. During the quarter ended June 30, 2021, 153,763 of these options were exercised. As of December 29, 2020, Legacy Danimer had 55,139 warrants outstanding with an exercise price of $ 30 per share. In connection with the Business Combination, these options were converted to options to purchase 506,611 shares of our common stock with an exercise price of $ 3.28 per share, and were exercised during the quarter ended March 31, 2021 on a cashless basis by issuing 435,961 shares. Anti-dilutive Instruments The following instruments were excluded from the calculation of diluted shares outstanding because the effect of including them would have been anti-dilutive. Three Months Ended June 30, Six Months Ended June 30,  2021  2020 2021  2020 Employee stock options 37,500  11,108,755 10,682,969  11,108,755 Public Warrants - - - - Private Warrants -  - 3,915,863  - Restricted shares - - 3,035,676 - Legacy Danimer options -  1,906,540 125,490  1,906,540 Legacy Danimer warrants - 506,611 - 506,611 Total excluded instruments 37,500 13,521,906 17,759,998 13,521,906

Revenue

Revenue	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue	Note 12. Revenue We recognize revenue from product sales and services in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). We derive our revenues primarily from: 1) product sales of developed compostable resins based on polylactic acid (“PLA”), polyhydroxyalkanoates (“PHA”), and other renewable materials; and 2) research and development (“R&D”) services related to developing customized formulations of biodegradable resins based on PHA. We generally produce and sell finished products, for which we recognize revenue upon shipment. Due to the highly specialized nature of our products, returns are infrequent, and therefore we do not estimate amounts for sales returns and allowances. There are no forms of variable consideration such as discounts, rebates, or volume discounts that we estimate to reduce our transaction price. We defer certain contract fulfillment costs. These costs are amortized to cost of revenue on a per-pound basis as we sell the related product. During the three and six months ended June 30, 2021, we charged $. 0.1 million and $ 0.3 million of fulfillment costs to cost of revenue. At June 30, 2021 and December 31, 2020 we had recorded gross contract assets of $ 2.0 million and $ 1.5 million, respectively, related to these fulfillment costs. R&D service revenues generally involve milestone-based contracts under which we work with a customer to develop a PHA-based specific solution designed to the customer’s specifications, which may involve a single or multiple performance obligations. At the inception of our R&D services contracts, customers generally pay consideration at the commencement of the agreement and at milestones as outlined in the contracts. We recognize contract liabilities for such progress with an input method based on personnel hours incurred to date as a percentage of total estimated personnel hours consideration initially, and then reduce each contract liability by recognizing revenue for our R&D services over time by measuring progress for each performance obligation identified within each contract. To the extent collectible revenue recognized under this method exceeds the consideration received, we recognize contract assets for unbilled consideration. The following table shows the significant changes in the R&D contract asset and contract liability balances for the six months ended June 30, 2021 and 2020. For the Six Months Ended June 30, 2021 2020 (in thousands) Contract Asset Contract Liability Total Revenue Recognized Contract Asset Contract Liability Total Revenue Recognized Beginning balance $ - $ ( 2,455 ) $ - $ ( 4,580 ) Revenue recognized 1,529 3,251 $ 4,780 - 1,256 $ 1,256 Unearned consideration received - ( 1,618 ) - ( 350 ) Ending balance $ 1,529 $ ( 822 ) $ 4,780 $ - $ ( 3,674 ) $ 1,256

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	Note 13. Stock-Based Compensation 2020 Equity Plans In connection with the Business Combination, on December 29, 2020, our stockholders approved the 2020 Incentive Plan and the 2020 Employee Stock Purchase Plan (“2020 ESPP Plan”). The 2020 Incentive Plan provides for the grant of stock options, stock appreciation rights, and full value awards. Full value awards include restricted stock, restricted stock units, deferred stock units, performance stock and performance stock units. Up to 3,093,984 shares of our common stock were authorized to be issued with respect to awards under the 2020 Incentive Plan. This limit is subject to adjustment in the event of a stock split, stock dividend or other changes in our capitalization. The 2020 ESPP Plan provides for the sale of our common stock to our employees through payroll withholding at a discount of 15 % from the lower of the closing price of our common stock on the first or last day of each biannual offering period. Up to 2,571,737 shares of our common stock were authorized to be issued under this plan. The first offering period under the 2020 ESPP Plan commenced on April 1, 2021 and we issued 5,013 shares effective June 30, 2021. Restricted Shares On March 10, 2021, we completed a Registration Form on Form S-8 to register the shares under the 2020 Equity Incentive Plan and the 2020 ESPP Plan. On this date, a grant of 3,035,676 shares of restricted stock was effective. The restrictions on half of these shares lapse ratably on the first, second, and third anniversaries of the grant date. The fair value of these shares on the date of grant was $ 37.09 and we are recognizing the compensation expense for these shares on a straight-line basis from the grant date through December 29, 2023. The restrictions on the other half of these shares lapse as follows: 1. On the first date the volume-weighted average price per share of our common stock equals or exceeds $ 24.20 for any 20 trading dates within a 30-day trading period beginning on December 29, 2021. 2. On the first date the volume-weighted average price per share of our common stock equals or exceeds $ 24.20 for any 20 trading dates within a 30-day trading period beginning on December 29, 2022. 3. On the first date the volume-weighted average price per share of our common stock equals or exceeds $ 24.20 for any 20 trading dates within a 30-day trading period beginning on December 29, 2023. To reflect the effect of this market condition on the vesting of these restricted shares, we valued them using a Monte Carlo simulation, which takes into account a large number of potential stock price scenarios over time and incorporates varied assumptions about volatility and exercise behavior for those various scenarios. A fair value is determined for each potential outcome. The grant date fair value of these restricted shares is the average of the fair values calculated for each potential outcome, or $ 36.57 . We are recognizing the compensation expense for these shares on a straight-line basis from the grant date through January 2024. No other grants of restricted shares have been made. Stock Options A summary of stock option activity under our equity plans for the six months ended June 30, 2021 follows:   Number of Shares  Weighted Average Exercise Price  Weighted Average Remaining Contractual Term (Years)  Aggregate Intrinsic Value Balance, December 31, 2020  11,008,533  $ 13.94  8.4  $ 105,341,482 Granted  37,500 $ 45.41   Exercised  ( 363,064 ) $ 3.28   $ 15,744,316 Balance, March 31, 2021  10,682,969  $ 14.41  8.0  $ 249,345,242 Granted  -    Exercised ( 200,532 ) $ 3.39 $ 5,616,689 Balance, June 30, 2021  10,482,437  $ 14.62   $ 109,293,775 Balance, June 30, 2021: Exercisable  4,791,353  $ 4.67  5.9  $ 97,647,774 Vested and expected to vest  10,482,437  $ 14.62  8.0  $ 109,293,775 The aggregate intrinsic values are calculated as the difference between the exercise price of the indicated stock options and the fair value of our common stock on the respective exercise dates or on June 30, 2021, as applicable. The weighted average grant-date fair values of options granted during the quarter ended March 31, 2021 was $ 18.52 per option. We have estimated the fair values of our option awards on the date of grant using the Black-Scholes option pricing model with the following assumptions:   Three and Six Months Ended June 30, 2021 Expected annual dividend yield (1)  0.00 % Expected volatility (2)  41.50 % Risk-free rate (3)  1.05 % Expected option term (years) (4)  6 (1) We have not paid and do not currently anticipate paying a cash dividend on our common stock. (2) We estimated the expected volatility using the mean stock price for selected peer public companies over a historic timeframe similar to the expected term. (3) We estimated the risk-free rate of return using the U.S. Treasury yield curve in effect as of the valuation date. (4) We estimated the expected term using the “simplified” method described in SEC Staff Accounting Bulletin 14. As of June 30, 2021, there was $ 143.0 million of unrecognized compensation cost related to nonvested stock options and restricted shares granted under the 2020 Incentive Plan. That cost is expected to be recognized over a weighted-average period of 2.5 years. During the quarter ended December 31, 2020, we awarded 1,466,874 stock options that are contingent upon shareholder approval of an increase in the number of shares issuable under the 2020 Incentive Plan, which has not occurred and which we determined is not a perfunctory exercise, therefore no accounting grant date has been established. As a result, these awards are not reflected in our consolidated financial statements. As described more fully in Note 15, these stock options were modified subsequent to June 30, 2021 and will be treated as liability awards.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14. Commitments and Contingencies Commitments In connection with our 2007 acquisition of certain intellectual property, we agreed to pay royalties upon production and sale of PHA. The royalty is $ 0.05 per pound for the first 500 million pounds of PHA sold and decreases to $ 0.025 per pound for cumulative sales in excess of that amount until the underlying patents expire. We incurred approximately $ 0.1 million in royalties during the six months ended June 30, 2021 In November 2015, we terminated a former executive and terminated our contract with an advisory firm (the “Advisory Contract”), pursuant to which we, through the advisory firm, engaged the individual as an executive of the Company. In December 2015, we deemed the Advisory Contract, together with all related arrangements in connection therewith, void, including any share issuances in connection with such arrangements. We filed suit against the former executive and the advisory firm during 2016, and various counterclaims were filed by the former executive and the advisory firm. During the third quarter of 2020, this matter was settled and we agreed to pay $ 8 million to resolve all outstanding claims, the executive agreed to the cancellation of any shares issued to such executive pursuant to the Advisory Contract and related arrangements, and the exchange of mutual releases among the parties. The remaining unpaid liability is included in accrued liabilities ( $ 1.3 . million and $ 1.3 million) and other long-term liabilities ($ 0.6 million and $ 1.3 million) at June 30, 2021 and December 31, 2020, respectively. Litigation Matters On May 14, 2021 a class action complaint was filed by Darryl Keith Rosencrants in the United States District Court for the Eastern District of New York, on May 19, 2021 a class action complaint was filed by Elizabeth and John Skistimas in the United States District Court for the Eastern District of New York, on May 18, 2021 a class action complaint was filed by Carlos Caballeros in the United States District Court for the Middle District of Georgia and on May 18, 2021 a class action complaint was filed by Dennis H. Wilkins also in the United States District Court for the Middle District of Georgia. Each plaintiff or plaintiffs brought the action individually and on behalf of all others similarly situated against the Company and/or Stephen E. Croskrey, John A. Dowdy, III, John P. Amboian, Richard J. Hendrix, Christy Basco, Philip Gregory Calhoun, Gregory Hunt, Isao Noda and Stuart W. Pratt (collectively, “Defendants”). The alleged class varies in each case but covers all persons and entities other than Defendants who purchased or otherwise acquired securities of the Company between October 5, 2020 and May 4, 2021 (the “Class Period”). Plaintiffs are seeking to recover damages caused by Defendants’ alleged violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the 1934 Act, and Rule 10b-5 promulgated thereunder. The complaints are substantially similar and are each premised upon various allegations that throughout the Class Period, Defendants made materially false and misleading statements regarding, among other things, the Company’s business, operations and compliance policies. Plaintiffs seek the following remedies: (i) determining that the lawsuits may be maintained as class actions under Rule 23 of the Federal Rules of Civil Procedure, (ii) certifying a class representative, (iii) requiring Defendants to pay damages allegedly sustained by plaintiffs and the class members by reason of the acts alleged in the complaints, and (iv) awarding pre-judgment and post-judgment interest as well as reasonable attorneys’ fees, expert fees and other costs. On July 29, 2021, the Georgia court transferred the Georgia cases to New York, motions to consolidate are pending and it is expected that all four class actions will be consolidated into a single lawsuit in the Eastern District of New York. When a consolidated class action complaint is filed, Defendants intend to make a motion to dismiss. On May 24, 2021, a shareholder derivative lawsuit was filed in the Court of Chancery of the State of Delaware by Richard Delman on behalf of the Company, alleging breach of fiduciary duty against the Company’s directors. That lawsuit has been stayed pending the outcome of Defendants’ motion to dismiss the securities class actions. The above complaints repeat certain allegations which are already in the public domain. Defendants deny the allegations of the complaints, believe the lawsuits are without merit and intend to defend them vigorously. Since the amounts of loss related to these matters, if any, cannot be reasonably estimated at this time, no amounts have been accrued for this matter at June 30, 2021.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 15. Subsequent Events Executive Compensation On July 23, 2021, in order to align our CEO compensation methodology with prevailing public company practices, the Compensation Committee of our Board of Directors and our Board of Directors approved our entering into an amended and restated employment agreement with our Chief Executive Officer and Chairman of the Board of Directors, Stephen E. Croskrey (“A&R Employment Agreement”). The A&R Employment Agreement provides, among other things, that Mr. Croskrey shall continue to serve as Chief Executive Officer and Chairman of the Board of Directors and provides for an annual base salary of $ 875,000 , effective as of January 1, 2021. Additionally, the A&R Employment Agreement provides that Mr. Croskrey is entitled to an immediate one-time bonus of $ 2,000,000 . The A&R Employment Agreement also provides that upon satisfaction of performance targets to be established by the Board of Directors, Mr. Croskrey will be paid an annual cash bonus equal to between 1.25 and 2.5 times his annual base salary if certain performance thresholds are attained. The A&R Employment Agreement states that in each year of employment, including 2021, Mr. Croskrey will receive a long term incentive award, of which 50% shall be in the form of performance stock awards that vest upon satisfaction of performance targets to be established by the Board of Directors for each such year and 50% shall be in the form of stock options that vest over time. If shares of common stock are not available to settle the awards as they come due, we will settle them in cash. The A&R Employment Agreement also modified all stock compensation instruments previously granted to Mr. Croskrey, which stipulated that if shares of common stock are not available to settle the awards as they come due, we will settle them in cash. We previously awarded Mr. Croskrey approximately 1.2 million options with an exercise price of $ 24.20 that are contingently granted upon on shareholder approval of an increase in the number of shares issuable under the 2020 Incentive Plan, which has not occurred, and therefore these awards not were reflected in our consolidated financial statements. The liability for these options will be marked to market each period end, with the income statement effect of such revaluations prorated through February 2024 and included in stock compensation expense reported within selling, general and administrative expense. The A&R Employment Agreement ends on December 31, 2024, unless earlier terminated in accordance with its terms. Director Compensation On August 12, 2021, we agreed to a modification of all stock compensation instruments previously granted to Mr. Stuart Pratt, Director, which stipulated that if shares of common stock are not available to settle the awards as they come due, we will settle them in cash. We previously awarded Mr. Pratt approximately 300 thousand options with an exercise price of $ 24.20 that are contingently granted upon on shareholder approval of an increase in the number of shares issuable under the 2020 Incentive Plan, which has not occurred, and therefore these awards were not reflected in our consolidated financial statements. The liability for these options will be marked to market each period end, with the income statement effect of such revaluations prorated through February 2024 and included in stock compensation expense reported within selling, general and administrative expense. Business Combination On July 28, 2021, we entered into an agreement and plan of merger (“Merger Agreement”) to acquire Novomer, Inc. in exchange for $ 152 million in cash, subject to certain customary adjustments as set forth in the Merger Agreement. We also entered into employment or consulting agreements with certain key employees and consultants of Novomer. We closed this transaction on August 11, 2021. We will issue option awards exercisable for shares of our common stock to certain continuing employees and continuing consultants of Novomer. The final purchase price determination is subject to customary post-close adjustments.

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Description of Business	Description of Business Danimer Scientific, Inc. (“Danimer”) together with its subsidiaries (collectively referred to as the “Company”) is a performance polymer company specializing in bioplastic replacements for traditional petroleum-based plastics. Our common stock is listed on the New York Stock Exchange under the symbol “DNMR”.
Recently Issued or Adopted Accounting Pronouncements	Recently Issued or Adopted Accounting Pronouncements There have been no new accounting pronouncements not yet effective or adopted in the current period that we believe have a significant effect, or potential significant effect, on our Financial Statements.
Income Taxes	Our effective income tax rate was zero for the three and six months ended June 30, 2021 and 2020 because we reported taxable losses in each period and continued to provide a full valuation allowance against our net deferred tax assets. In assessing the realizability of deferred income tax assets, we consider whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods at which time those temporary differences become deductible. In making valuation allowance determinations, we consider all available evidence, positive and negative, affecting specific deferred tax assets, including the scheduled reversal of deferred income tax liabilities, projected future taxable income, the length of carry-back and carry-forward periods, and tax planning strategies in making this assessment.
Revenue	We recognize revenue from product sales and services in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). We derive our revenues primarily from: 1) product sales of developed compostable resins based on polylactic acid (“PLA”), polyhydroxyalkanoates (“PHA”), and other renewable materials; and 2) research and development (“R&D”) services related to developing customized formulations of biodegradable resins based on PHA. We generally produce and sell finished products, for which we recognize revenue upon shipment. Due to the highly specialized nature of our products, returns are infrequent, and therefore we do not estimate amounts for sales returns and allowances. There are no forms of variable consideration such as discounts, rebates, or volume discounts that we estimate to reduce our transaction price. We defer certain contract fulfillment costs. These costs are amortized to cost of revenue on a per-pound basis as we sell the related product. During the three and six months ended June 30, 2021, we charged $. 0.1 million and $ 0.3 million of fulfillment costs to cost of revenue. At June 30, 2021 and December 31, 2020 we had recorded gross contract assets of $ 2.0 million and $ 1.5 million, respectively, related to these fulfillment costs. R&D service revenues generally involve milestone-based contracts under which we work with a customer to develop a PHA-based specific solution designed to the customer’s specifications, which may involve a single or multiple performance obligations. At the inception of our R&D services contracts, customers generally pay consideration at the commencement of the agreement and at milestones as outlined in the contracts. We recognize contract liabilities for such progress with an input method based on personnel hours incurred to date as a percentage of total estimated personnel hours consideration initially, and then reduce each contract liability by recognizing revenue for our R&D services over time by measuring progress for each performance obligation identified within each contract. To the extent collectible revenue recognized under this method exceeds the consideration received, we recognize contract assets for unbilled consideration.

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Schedule of inventory	Inventories consisted of the following: June 30, December 31, (in thousands) 2021 2020 Raw materials $ 7,650 $ 6,825 Work in progress - 133 Finished goods and related items 10,003 6,684 Total inventories $ 17,653 $ 13,642

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property, plant, and equipment, net	Property, plant and equipment, net, consisted of the following: Estimated Useful Life June 30, December 31, (in thousands) (Years) 2021 2020 Land and improvements 20 $ 92 $ 92 Leasehold improvements Shorter of useful 21,021 20,932 Buildings 15 - 40 2,089 2,089 Machinery and equipment 5 - 20 82,489 64,164 Motor vehicles 7 - 10 874 693 Furniture and fixtures 7 - 10 229 221 Office equipment 3 - 10 2,110 2,089 Construction in progress N/A 74,771 36,146 183,675 126,426 Accumulated depreciation and amortization ( 23,692 ) ( 19,631 ) Property, plant and equipment, net $ 159,983 $ 106,795
Schedule of depreciation and amortization expense	We reported depreciation and amortization expense (which included amortization of patents) as follows: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2021 2020 2021 2020 Cost of revenue $ 1,951 $ 753 $ 3,790 $ 1,436 Selling, general and administrative 177 31 273 60 Research and development 83 155 248 313 Total depreciation and amortization expense $ 2,211 $ 939 $ 4,311 $ 1,809

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Accrued Liabilities [Abstract]
Schedule of accrued liabilities	The components of accrued liabilities were as follows: June 30, December 31, (in thousands) 2021 2020 Compensation and related expenses $ 1,407 $ 5,395 Legal settlement 1,250 1,250 Transaction costs and other legal fees 1,563 1,293 Construction in progress expenditures - 531 Other 1,681 751 Total accrued liabilities $ 5,901 $ 9,220

Operating Leases (Tables)

Operating Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Text Block [Abstract]
Schedule of operating lease costs	We reported operating lease costs as follows: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2021 2020 2021 2020 Cost of revenue $ 83 $ 244 $ 613 $ 460 Selling, general and administrative ( 91 ) 496 ( 40 ) 951 Research and development 144 129 288 245 Total operating lease cost $ 136 $ 869 $ 861 $ 1,656

Private Warrants (Tables)

Private Warrants (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Measurement Inputs and Valuation Techniques [Abstract]
Schedule of Private Warrants Fair Value Measurement Valuation	The table below sets forth the inputs we used in our Black-Scholes models for Private Warrant valuations and the fair values determined. As Of Three Months Ended Six Months Ended As Of June 30, 2021 June 30, 2021 June 30, 2021 December 31, 2020 Share price of our common stock $ 25.05 $ 17.45 - $ 38.33 $ 17.45 - $ 44.26 $ 23.51 Expected annual dividend yield (1) 0 % 0 % 0 % 0 % Expected volatility (2) 40 % 40 % 40 % 40.0 % Risk-free rate of return (3) 0.76 % 0.76 % 0.76 % - 0.85 % 0.36 % Expected warrant term (years) (4) 4.50 4.50 - 4.73 4.50 - 4.99 4.99 Fair value determined per warrant $ 15.14 $ 8.53 - $ 27.82 $ 8.53 - $ 33.65 $ 13.81 (1) We have not paid and do not currently anticipate paying a cash dividend on our common stock. (2) We estimated expected volatilities using stock data for select peer public companies over a timeframe similar to the expected term. We selected peer companies using our judgment and as such, expected volatility is a Level 3 input. (3) We estimated risk-free rates based on the expected terms using the U.S. Treasury yield curve in effect as of the valuation dates. (4) The expected warrant terms are equal to the remaining contractual life of the Private Warrants at each measurement date.
Summary of Rollforward of Private Warrants Liability	A rollforward of the Private Warrants liability is below. (in thousands) Balance at December 31, 2020 $ ( 82,860 ) Loss on remeasurement of Private Warrants ( 80,697 ) Fair value of Private Warrants sold 13,922 Balance at March 31, 2021 ( 149,635 ) Gain on remeasurement of Private Warrants 58,740 Fair value of Private Warrants sold 31,593 Balance at June 30, 2021 $ ( 59,302 )

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Schedule of long-term debt	The components of long-term debt were as follows: June 30, December 31, (in thousands) 2021 2020 2019 Term Loan $ - $ 27,000 Subordinated Term Loan 10,205 10,171 NMTC notes 21,000 21,000 Paycheck Protection Program loan - 1,776 Asset Based Lending Agreement - - Vehicle and equipment notes 434 329 Mortgage notes 254 266 Total $ 31,893 $ 60,542 Less: Total unamortized debt issuance costs ( 1,984 ) ( 3,955 ) Less: Current cash maturities net of current portion of debt issuance costs ( 333 ) ( 25,201 ) Total long-term debt $ 29,576 $ 31,386

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jun. 30, 2021
Stockholders' Equity Note [Abstract]
Schedule of common stock outstanding	The following table summarizes the common stock activity for the three and six months ended June 30, 2021 and 2020: Three Months Ended Six Months Ended June 30, June 30, 2021 2020 (1) 2021 2020 (1) Common stock: Balance, beginning of period 85,339,145 29,005,309 84,535,640 25,371,186 Issuance of common stock 12,392,934 - 13,196,439 3,634,123 Balance, end of period 97,732,079 29,005,309 97,732,079 29,005,309 (1) Retroactively restated for Business Combination
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following instruments were excluded from the calculation of diluted shares outstanding because the effect of including them would have been anti-dilutive. Three Months Ended June 30, Six Months Ended June 30,  2021  2020 2021  2020 Employee stock options 37,500  11,108,755 10,682,969  11,108,755 Public Warrants - - - - Private Warrants -  - 3,915,863  - Restricted shares - - 3,035,676 - Legacy Danimer options -  1,906,540 125,490  1,906,540 Legacy Danimer warrants - 506,611 - 506,611 Total excluded instruments 37,500 13,521,906 17,759,998 13,521,906

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Schedule of changes in R&D contract asset and contract liability balance	The following table shows the significant changes in the R&D contract asset and contract liability balances for the six months ended June 30, 2021 and 2020. For the Six Months Ended June 30, 2021 2020 (in thousands) Contract Asset Contract Liability Total Revenue Recognized Contract Asset Contract Liability Total Revenue Recognized Beginning balance $ - $ ( 2,455 ) $ - $ ( 4,580 ) Revenue recognized 1,529 3,251 $ 4,780 - 1,256 $ 1,256 Unearned consideration received - ( 1,618 ) - ( 350 ) Ending balance $ 1,529 $ ( 822 ) $ 4,780 $ - $ ( 3,674 ) $ 1,256

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of stock option activity under our equity plans	A summary of stock option activity under our equity plans for the six months ended June 30, 2021 follows:   Number of Shares  Weighted Average Exercise Price  Weighted Average Remaining Contractual Term (Years)  Aggregate Intrinsic Value Balance, December 31, 2020  11,008,533  $ 13.94  8.4  $ 105,341,482 Granted  37,500 $ 45.41   Exercised  ( 363,064 ) $ 3.28   $ 15,744,316 Balance, March 31, 2021  10,682,969  $ 14.41  8.0  $ 249,345,242 Granted  -    Exercised ( 200,532 ) $ 3.39 $ 5,616,689 Balance, June 30, 2021  10,482,437  $ 14.62   $ 109,293,775 Balance, June 30, 2021: Exercisable  4,791,353  $ 4.67  5.9  $ 97,647,774 Vested and expected to vest  10,482,437  $ 14.62  8.0  $ 109,293,775
Schedule of option award on the date of grant using the Black-Scholes option	We have estimated the fair values of our option awards on the date of grant using the Black-Scholes option pricing model with the following assumptions:   Three and Six Months Ended June 30, 2021 Expected annual dividend yield (1)  0.00 % Expected volatility (2)  41.50 % Risk-free rate (3)  1.05 % Expected option term (years) (4)  6 (1) We have not paid and do not currently anticipate paying a cash dividend on our common stock. (2) We estimated the expected volatility using the mean stock price for selected peer public companies over a historic timeframe similar to the expected term. (3) We estimated the risk-free rate of return using the U.S. Treasury yield curve in effect as of the valuation date. (4) We estimated the expected term using the “simplified” method described in SEC Staff Accounting Bulletin 14.

Basis of Presentation (Details)

Basis of Presentation (Details) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Description of Business and Basis of Presentation (Details) [Line Items]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001

Business Combination (Details)

Business Combination (Details)	3 Months Ended
	Mar. 31, 2021shares
Business Combination (Details) [Line Items]
Share of common stock (in Shares)	435,961

Inventories (Details) - Schedul

Inventories (Details) - Schedule of inventory - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Schedule of inventory [Abstract]
Raw materials	$ 7,650	$ 6,825
Work in progress	0	133
Finished goods and related items	10,003	6,684
Total inventories	$ 17,653	$ 13,642

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - Schedule of Property, plant, and equipment, net - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 183,675	$ 126,426
Accumulated depreciation and amortization	(23,692)	(19,631)
Property, plant and equipment, net	$ 159,983	106,795
Land and improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	20 years
Property and equipment, gross	$ 92	92
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 21,021	20,932
Estimated Useful Life	Shorter of usefullife or lease term
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,089	2,089
Buildings [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	15 years
Buildings [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	40 years
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 82,489	64,164
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	20 years
Motor vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 874	693
Motor vehicles [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	7 years
Motor vehicles [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 229	221
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	7 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,110	2,089
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Construction-in-progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 74,771	$ 36,146

Property, Plant and Equipment_3

Property, Plant and Equipment (Details) - Schedule of depreciation and amortization expense - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Depreciation and amortization expense	$ 2,211	$ 939	$ 4,311	$ 1,809
Cost of revenue [Member]
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Depreciation and amortization expense	1,951	753	3,790	1,436
Selling, general, and administrative [Member]
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Depreciation and amortization expense	177	31	273	60
Research & development [Member]
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Depreciation and amortization expense	$ 83	$ 155	$ 248	$ 313

Property, Plant and Equipment_4

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Property, plant, and equipment includes capitalized interest		$ 5,300		$ 5,300		$ 5,100
Property, Plant and Equipment interest costs		$ 100	$ 1,100	$ 300	$ 1,800
Prepaid expenses and other current assets						$ 800
Loss on Sale of Equipment	$ 33

Patents (Details)

Patents (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Intangible asset not yet subject to amortization	$ 0.7		$ 0.7		$ 0.5
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	7.8		7.8		7.8
Finite-Lived Intangible Assets, Accumulated Amortization	6.7		6.7		$ 6.5
Patents [Member] | Research and Development Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 0.1	$ 0.2	$ 0.1	$ 0.2
Patents [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life			16 years
Patents [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life			13 years

Accrued Liabilities (Details) -

Accrued Liabilities (Details) - Schedule of accrued liabilities - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Schedule of accrued liabilities [Abstract]
Compensation and related expenses	$ 1,407	$ 5,395
Legal settlement	1,250	1,250
Transaction costs and other legal fees	1,563	1,293
Construction in progress expenditures	0	531
Other	1,681	751
Total accrued liabilities	$ 5,901	$ 9,220

Income Taxes (Additional Inform

Income Taxes (Additional Information) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0	$ 0	$ 0

Operating Leases (Details) - Sc

Operating Leases (Details) - Schedule of operating lease costs - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Total operating lease cost	$ 136	$ 869	$ 861	$ 1,656
Cost of revenue [Member]
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Total operating lease cost	83	244	613	460
Selling, general and administrative [Member]
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Total operating lease cost	(91)	496	(40)	951
Research and development [Member]
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Total operating lease cost	$ 144	$ 129	$ 288	$ 245

Private Warrants (Details)

Private Warrants (Details) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Dec. 31, 2020	Dec. 29, 2020
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding					55,139
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 30
Public Warrants
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding				10,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 11.50
Private Warrants
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	3,915,893		3,915,893	6,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 11.50		$ 11.50	$ 11.50
Class of Warrant or Right, Date from which Warrants or Rights Exercisable			May 7, 2021
Warrants and Rights Outstanding, Maturity Date	Dec. 28, 2025		Dec. 28, 2025
Number of Warrants Sold During Period	1,565,260	518,847

Private Warrants - Summary of R

Private Warrants - Summary of Rollforward of Private Warrants Liability (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Class of Warrant or Right [Line Items]
Balance	$ (149,635)	$ (82,860)		$ (82,860)
Gain (loss) on remeasurement of private warrants	58,740	(80,697)	$ 0	(21,957)	$ 0
Fair value of Private Warrants sold	31,593	13,922
Balance	$ (59,302)	$ (149,635)		$ (59,302)

Private Warrants - Schedule of

Private Warrants - Schedule of Fair Value Valuation of Private Warrants (Details)		3 Months Ended		6 Months Ended
		Jun. 30, 2021USD ($)		Jun. 30, 2021USD ($)		Dec. 31, 2020USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	[1]					0.400
Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Output		15.14		15.14		13.81
Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input		25.05		25.05		23.51
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	[2]	0		0		0
Warrants and Rights Outstanding, Measurement Input	[2]			0
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	[1]	0.40		0.40
Warrants and Rights Outstanding, Measurement Input	[1]	0.40		0.40
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input		0.0076	[3]	0.0076	[3]	0.0036
Warrants and Rights Outstanding, Measurement Input	[3]	0.0076
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Term	[4]	4 years 6 months		4 years 6 months		4 years 11 months 26 days
Warrants and Rights Outstanding, Measurement Input	[2]	0
Maximum [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input		27.82		33.65
Maximum [Member] | Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input		38.33		44.26
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	[3]			0.0085
Maximum [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Term	[4]	4 years 8 months 23 days		4 years 11 months 26 days
Minimum [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input		8.53		8.53
Minimum [Member] | Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input		17.45		17.45
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	[3]			0.0076
Minimum [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Term	[4]	4 years 6 months		4 years 6 months
[1]	We estimated expected volatilities using stock data for select peer public companies over a timeframe similar to the expected term. We selected peer companies using our judgment and as such, expected volatility is a Level 3 input.
[2]	We have not paid and do not currently anticipate paying a cash dividend on our common stock.
[3]	We estimated risk-free rates based on the expected terms using the U.S. Treasury yield curve in effect as of the valuation dates.
[4]	The expected warrant terms are equal to the remaining contractual life of the Private Warrants at each measurement date.

Debt (Details) - Schedule of lo

Debt (Details) - Schedule of long-term debt - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	$ 31,893	$ 60,542
Less: Total unamortized debt issuance costs	(1,984)	(3,955)
Less: Current cash maturities net of current portion of debt issuance costs	(333)	(25,201)
Total long-term debt	29,576	31,386
2019 Term Loan [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total		27,000
2019 Subordinated Term Loan [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	10,205	10,171
NMTC Notes [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	21,000	21,000
Paycheck Protection Program loan
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	0	1,776
Asset Backed Lending Arrangement [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	0	0
Vehicle and Equipment Notes [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	434	329
Mortgage Notes [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total	$ 254	$ 266

Debt (Details)

Debt (Details) - USD ($)

Apr. 29, 2021

Mar. 18, 2021

Mar. 31, 2019

Jul. 31, 2020

Mar. 31, 2019

Jun. 30, 2021

Mar. 31, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Dec. 31, 2020

Jan. 29, 2021

Apr. 30, 2020

Long-Term Debt (Details) [Line Items]

Unrestricted cash on deposit

$ 416,355,000

$ 416,355,000

$ 377,581,000

Gain on forgiveness of debt

0

$ 0

2,604,000

$ 0

Interest expense

$ 222,000

$ 384,000

422,000

$ 1,097,000

2019 Term Loan [Member]

Long-Term Debt (Details) [Line Items]

Maturity date

Oct. 13, 2023

Oct. 13, 2023

Aggregate principal amount

$ 30,000,000

$ 30,000,000

Principle payment

375,000

Interest rate formula, description

the applicable margin in the interest rate formula (formerly calculated as the greater of (a) 2.25% or (b) three month LIBOR, plus 4.5%) changed from 4.5% to a five-level tiered amount ranging from 4.5% if the consolidated senior leverage ratio, as defined in the 2019 Term Loan, was less than 1.5, to as high as 6.35% if the consolidated senior leverage ratio was greater than 2.25.  When the amendment was executed, the applicable margin was 6.35%.

Prepaid total amount

$ 27,700,000

Outstanding principal amount

27,000,000

Prepayment fee

500,000

Accrued unpaid interest

$ 200,000

Debt instrument, basis spread on variable rate

2.25%

2019 Subordinated Term Loan [Member]

Long-Term Debt (Details) [Line Items]

Subordinated term loan

10,000,000

$ 10,000,000

Interest rate basis

The base interest rate is the “Prime Rate” as quoted by the Wall Street Journal (adjusted each calendar quarter; 3.25% and 3.25% at June 30, 2021 and December 31, 2020, respectively) plus 2.75%. We have the option to pay up to two percent (2%) in any interest payable in any fiscal quarter by adding such interest payment to the principal balance of the related note (“PIK Interest”).

Debt base rate

3.25%

3.25%

Additional principal amount

$ 200,000

Option to pay interest payable

2.00%

2019 Subordinated Term Loan [Member] | Prime Rate [Member]

Long-Term Debt (Details) [Line Items]

Debt instrument, basis spread on variable rate

2.00%

2.75%

Paycheck Protection Program loan [Member]

Long-Term Debt (Details) [Line Items]

Aggregate principal amount

$ 1,800,000

Interest rate

1.00%

Escrow deposit

$ 1,800,000

Gain on forgiveness of debt

1,800,000

Gain on Debt Instrument

$ 1,800,000

Revolving Loans [Member]

Long-Term Debt (Details) [Line Items]

Debt instrument, basis spread on variable rate

1.00%

Revolving Loans [Member] | Base Rate [Member]

Long-Term Debt (Details) [Line Items]

Debt instrument, basis spread on variable rate

1.50%

Revolving Loans [Member] | LIBOR Market Index Rate [Member]

Long-Term Debt (Details) [Line Items]

Debt instrument, basis spread on variable rate

2.50%

Equipment Loans [Member] | Base Rate [Member]

Long-Term Debt (Details) [Line Items]

Debt instrument, basis spread on variable rate

1.75%

Equipment Loans [Member] | LIBOR Market Index Rate [Member]

Long-Term Debt (Details) [Line Items]

Debt instrument, basis spread on variable rate

2.75%

LIMR Loan [Member]

Long-Term Debt (Details) [Line Items]

Debt instrument, basis spread on variable rate

2.00%

Minimum [Member] | 2019 Term Loan [Member] | Three Month LIBOR [Member]

Long-Term Debt (Details) [Line Items]

Debt instrument, basis spread on variable rate

4.50%

Minimum [Member] | 2019 Subordinated Term Loan [Member]

Long-Term Debt (Details) [Line Items]

Unrestricted cash on deposit

$ 10,000,000

Maximum [Member]

Long-Term Debt (Details) [Line Items]

Claim Percentage Against Federal Income Taxes Of Qualified Investment

39.00%

Maximum [Member] | 2019 Term Loan [Member] | Three Month LIBOR [Member]

Long-Term Debt (Details) [Line Items]

Debt instrument, basis spread on variable rate

6.35%

Term Loan One [Member] | 2019 Subordinated Term Loan [Member]

Long-Term Debt (Details) [Line Items]

Subordinated term loan

5,500,000

$ 5,500,000

Term Loan Two [Member] | 2019 Subordinated Term Loan [Member]

Long-Term Debt (Details) [Line Items]

Subordinated term loan

$ 4,500,000

$ 4,500,000

Asset Backed Lending Arrangement [Member]

Long-Term Debt (Details) [Line Items]

Interest rate basis

a base rate (as defined in the Credit Agreement) plus an applicable margin of 1.50% for revolving loans and 1.75% for equipment loans, or a LIBOR market index rate (“LMIR”) (as defined) plus an applicable margin of 2.50% for revolving loans and 2.75% for equipment loans. If we maintain a trailing twelve month consolidated fixed charge coverage ratio (as defined) of 1.1:1.0 or better and no event of default exists, then the applicable margins for base rate revolving loans and LMIR rate loans are 1.00% and 2.00%, respectively.

Truist bank [Member]

Long-Term Debt (Details) [Line Items]

Debt Instrument, Maturity Date

Apr. 29, 2026

Truist bank [Member] | Asset Backed Lending Arrangement [Member]

Long-Term Debt (Details) [Line Items]

Line of Credit Facility

$ 20,000,000

Truist bank [Member] | Capital Expenditure line [Member]

Long-Term Debt (Details) [Line Items]

Line of Credit Facility

$ 1,000,000

Equity - Summary of the common

Equity - Summary of the common stock activity (Details) - shares	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	[1]
Stockholders' Equity Note [Abstract]
Balance, beginning of period	85,339,145	84,535,640	25,371,186
Issuance of common stock	12,392,934	13,196,439	3,634,123
Balance, end of period	97,732,079	97,732,079	29,005,309
[1]	(1) Retroactively restated for Business Combination

Equity (Details)

Equity (Details) - USD ($) $ / shares in Units, $ in Millions	Dec. 29, 2020	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2016	Jun. 30, 2020	[1]	Mar. 31, 2020	[1]	Dec. 31, 2019	[1]
Stockholders' Equity (Details) [Line Items]
Common Stock, Shares, Outstanding		97,732,079	85,339,145	97,732,079	84,535,640		29,005,309		29,005,309		25,371,186
Outstanding warrants (in Shares)	55,139
Warrant price per share	$ 30
Options Issued						208,183
Weighted Average Exercise Price of per share (in Dollars per share)	$ 30
Number of shares, exercised		(200,532)	(363,064)
Conversion of Stock, Shares Converted	279,253				506,611
Class of Warrant or Right, Outstanding	55,139
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 30
Conversion of Stock, Shares Issued			435,961
Weighted Average Exercise Price, Exercised (in Dollars per share)	$ 3.28	$ 3.39	$ 3.28		$ 3.28
Public Warrants
Stockholders' Equity (Details) [Line Items]
Price per share		$ 18		$ 18
Warrants And Rights Exercised		12,033,169		12,033,169
Warrants And Rights Redeemed		50,965		50,965
Proceeds from Warrant Exercises				$ 138.2
Outstanding warrants (in Shares)					10,000,000
Warrant price per share					$ 11.50
Redeemable outstanding warrants price		$ 0.01		$ 0.01
Class of Warrant or Right, Outstanding					10,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 11.50
Legacy Danimer options
Stockholders' Equity (Details) [Line Items]
Number of shares, exercised				(153,763)
Exercisable and remained outstanding ( in shares)	30,493
[1]	(1) Retroactively restated for Business Combination

Equity (Details) Antidilutive S

Equity (Details) Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	37,500	13,521,906	17,759,998	13,521,906
Employee Stock Option Member
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	37,500	11,108,755	10,682,969	11,108,755
Private Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			3,915,863
Restricted Shares
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			3,035,676
Legacy Danimer warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		506,611		506,611
Legacy Danimer options
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		1,906,540	125,490	1,906,540

Revenue (Details)

Revenue (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Fulfillment costs to cost of revenue	$ 0.1	$ 0.3
Contract assets recorded related to fulfillment costs	$ 2	$ 2	$ 1.5

Revenue (Details) - Change in C

Revenue (Details) - Change in Contract Asset and Contract Liability Balance - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Beginning balance, Contract Liability	$ (2,455)	$ (4,580)
Revenue Recognized	3,251	1,256
Unearned consideration received	(1,618)	(350)
Ending Balance, Contract Liability	(822)	(3,674)
Beginning Balance, Contract Asset	0	0
Revenue recognized	1,529	0
Unearned consideration received	0
Ending Balance, Contract Asset	1,529	0
Total Revenue Recognized	$ 4,780	$ 1,256

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	[1]	Mar. 10, 2021
Stock-Based Compensation (Details) [Line Items]
Performance stock and performance stock units	12,392,934			13,196,439	3,634,123
Employee share purchase plan, description				Up to 2,571,737 shares of our common stock were authorized to be issued under this plan. The first offering period under the 2020 ESPP Plan commenced on April 1, 2021 and we issued 5,013 shares effective June 30, 2021.
Weighted average grant-date fair value of options granted (in Dollars per share)		$ 18.52
Restricted stock shares							3,035,676
Unrecognized compensation cost related to nonvested stock options grant (in Dollars)	$ 143			$ 143
Weighted-average over period				2 years 6 months
First anniversary [Member]
Stock-Based Compensation (Details) [Line Items]
Common stock equals or exceeds (in Dollars per share)	$ 24.20			$ 24.20
Second anniversary [Member]
Stock-Based Compensation (Details) [Line Items]
Common stock equals or exceeds (in Dollars per share)	24.20			24.20
Third anniversary [Member]
Stock-Based Compensation (Details) [Line Items]
Common stock equals or exceeds (in Dollars per share)	$ 24.20			$ 24.20
2020 ESPP [Member]
Stock-Based Compensation (Details) [Line Items]
ESPP plan, percentage of stock discount				15.00%
Share-based compensation, authorized shares	2,571,737			2,571,737
Share-based compensation, Issued shares				5,013
Fair value of restricted stock on the date of grant (in dollar per share)							$ 36.57
2020 Incentive Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Share-based compensation, authorized shares	3,093,984			3,093,984
Fair value of restricted stock on the date of grant (in dollar per share)							$ 37.09
Stock options			1,466,874
[1]	(1) Retroactively restated for Business Combination

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of stock option activity under our equity plans - USD ($)	Dec. 29, 2020	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Stock-Based Compensation (Details) - Schedule of stock option activity under our equity plans [Line Items]
Number of Shares, Beginning		10,682,969	11,008,533	11,008,533
Number of Shares, Granted			37,500
Number of shares, exercised		(200,532)	(363,064)
Number of Shares, Ending		10,482,437	10,682,969	10,482,437	11,008,533
Number of Shares, Exercisable		4,791,353		4,791,353
Number of Shares, Vested and expected to vest		10,482,437		10,482,437
Weighted Average Exercise Price, Beginning (in Dollars per share)		$ 14.41	$ 13.94	$ 13.94
Weighted Average Exercise Price, Granted (in Dollars per share)			45.41
Weighted Average Exercise Price, Exercised (in Dollars per share)	$ 3.28	3.39	3.28		$ 3.28
Weighted Average Exercise Price, Ending (in Dollars per share)		14.62	$ 14.41	14.62	$ 13.94
Weighted Average Exercise Price, Exercisable (in Dollars per share)		4.67		4.67
Weighted Average Exercise Price, Vested and expected to vest (in Dollars per share)		$ 14.62		$ 14.62
Weighted Average Remaining Contractual Term (Years), Beginning					8 years 4 months 24 days
Weighted Average Remaining Contractual Term (Years), Ending			8 years
Weighted Average Remaining Contractual Term (Years), Exercisable				5 years 10 months 24 days
Weighted Average Remaining Contractual Term (Years), Vested and expected to vest				8 years
Aggregate Intrinsic Value, Beginning (in Dollars)		$ 249,345,242	$ 105,341,482	$ 105,341,482
Aggregate Intrinsic Value, Exercised (in Dollars)		5,616,689	15,744,316
Aggregate Intrinsic Value, Ending (in Dollars)		109,293,775	$ 249,345,242	109,293,775	$ 105,341,482
Aggregate Intrinsic Value, Exercisable (in Dollars)		97,647,774		97,647,774
Aggregate Intrinsic Value, Vested and expected to vest (in Dollars)		$ 109,293,775		$ 109,293,775

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of option award on the date of grant using the Black-Scholes option		3 Months Ended	6 Months Ended
		Jun. 30, 2021	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Expected annual dividend yield	[1]	0.00%	0.00%
Expected volatility	[2]	41.50%	41.50%
Risk-free rate of return	[3]	1.05%	1.05%
Expected option term (years)	[4]	6 years	6 years
[1]	We have not paid and do not currently anticipate paying a cash dividend on our common stock.
[2]	We estimated the expected volatility using the mean stock price for selected peer public companies over a historic timeframe similar to the expected term.
[3]	We estimated the risk-free rate of return using the U.S. Treasury yield curve in effect as of the valuation date.
[4]	We estimated the expected term using the “simplified” method described in SEC Staff Accounting Bulletin 14.

Commitments and Contingencies (

Commitments and Contingencies (Details) $ / shares in Units, ج.م. in Millions, $ in Millions	3 Months Ended	6 Months Ended
	Sep. 30, 2020USD ($)	Jun. 30, 2021EGP (ج.م.)	Jun. 30, 2021USD ($)$ / shares	Dec. 31, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
Royalty per share (in Pounds per share) | $ / shares			$ 0.05
Sold of PHA (in Pounds) | ج.م.		ج.م. 500
Decrease royalty per share (in Pounds per share) | $ / shares			$ 0.025
Royalties amount			$ 0.1
Outstanding claims amount	$ 8
Accrued expenses			1.3	$ 1.3
Other long-term liabilities			$ 0.6	$ 1.3

Subsequent Events (Details)

Subsequent Events (Details) $ / shares in Units, shares in Thousands	Aug. 12, 2021$ / sharesshares	Jul. 28, 2021USD ($)	Jul. 23, 2021USD ($)$ / sharesshares	Jun. 30, 2021
A&R Employment Agreement [Member]
Subsequent Event [Line Items]
Deferred compensation arrangements, overall, description				The A&R Employment Agreement states that in each year of employment, including 2021, Mr. Croskrey will receive a long term incentive award, of which 50% shall be in the form of performance stock awards that vest upon satisfaction of performance targets to be established by the Board of Directors for each such year and 50% shall be in the form of stock options that vest over time. If shares of common stock are not available to settle the awards as they come due, we will settle them in cash.The A&R Employment Agreement also modified all stock compensation instruments previously granted to Mr. Croskrey, which stipulated that if shares of common stock are not available to settle the awards as they come due, we will settle them in cash. We previously awarded Mr. Croskrey approximately 1.2 million options with an exercise price of $24.20 that are contingently granted upon on shareholder approval of an increase in the number of shares issuable under the 2020 Incentive Plan, which has not occurred, and therefore these awards not were reflected in our consolidated financial statements. The liability for these options will be marked to market each period end, with the income statement effect of such revaluations prorated through February 2024 and included in stock compensation expense reported within selling, general and administrative expense.The A&R Employment Agreement ends on December 31, 2024, unless earlier terminated in accordance with its terms.
Subsequent Event [Member] | A&R Employment Agreement [Member]
Subsequent Event [Line Items]
Salary and Wage, Officer			$ 875,000
Bonus, Officer			$ 2,000,000
Subsequent Event [Member] | Mr Croskrey [Member] | 2020 Incentive Plan [Member] | A&R Employment Agreement [Member]
Subsequent Event [Line Items]
Number of Stock Options, Contingent Grants | shares			1,200
Stock Options, Exercise Price, Contingent Grants | $ / shares			$ 24.20
Subsequent Event [Member] | Mr Pratt [Member] | 2020 Incentive Plan [Member]
Subsequent Event [Line Items]
Number of Stock Options, Contingent Grants | shares	300
Stock Options, Exercise Price, Contingent Grants | $ / shares	$ 24.20
Subsequent Event [Member] | Novomer Inc [Member]
Subsequent Event [Line Items]
Payments to Acquire Businesses, Gross		$ 152,000,000
Subsequent Event [Member] | Maximum [Member] | A&R Employment Agreement [Member]
Subsequent Event [Line Items]
Annual Cash Bonus Ratio			2.5
Subsequent Event [Member] | Minimum [Member] | A&R Employment Agreement [Member]
Subsequent Event [Line Items]
Annual Cash Bonus Ratio			1.25